日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Proteus mirabilis UPF0208 membrane protein PMI1770 (PMI1770), partial CSB-YP461510EYZ1
CSB-EP461510EYZ1
CSB-BP461510EYZ1
CSB-MP461510EYZ1
CSB-EP461510EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Chorismate synthase (aroC) CSB-YP461511EYZ
CSB-EP461511EYZ
CSB-BP461511EYZ
CSB-MP461511EYZ
CSB-EP461511EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (ispG) CSB-YP461512EYZ
CSB-EP461512EYZ
CSB-BP461512EYZ
CSB-MP461512EYZ
CSB-EP461512EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis tRNA1 (Val) (adenine (37)-N6)-methyltransferase CSB-YP461513EYZ
CSB-EP461513EYZ
CSB-BP461513EYZ
CSB-MP461513EYZ
CSB-EP461513EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Aspartate--ammonia ligase (asnA) CSB-YP461514EYZ
CSB-EP461514EYZ
CSB-BP461514EYZ
CSB-MP461514EYZ
CSB-EP461514EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis ATP synthase subunit c (atpE), partial CSB-YP461515EYZ1
CSB-EP461515EYZ1
CSB-BP461515EYZ1
CSB-MP461515EYZ1
CSB-EP461515EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Peptide chain release factor 2 (prfB) CSB-YP461516EYZ
CSB-EP461516EYZ
CSB-BP461516EYZ
CSB-MP461516EYZ
CSB-EP461516EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis tRNA modification GTPase MnmE (mnmE) CSB-YP461517EYZ
CSB-EP461517EYZ
CSB-BP461517EYZ
CSB-MP461517EYZ
CSB-EP461517EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Orotate phosphoribosyltransferase (pyrE) CSB-YP461518EYZ
CSB-EP461518EYZ
CSB-BP461518EYZ
CSB-MP461518EYZ
CSB-EP461518EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UPF0289 protein PMI2053 (PMI2053) CSB-YP461519EYZ
CSB-EP461519EYZ
CSB-BP461519EYZ
CSB-MP461519EYZ
CSB-EP461519EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase CSB-YP461520EYZ
CSB-EP461520EYZ
CSB-BP461520EYZ
CSB-MP461520EYZ
CSB-EP461520EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis ADP-L-glycero-D-manno-heptose-6-epimerase (hldD) CSB-YP461521EYZ
CSB-EP461521EYZ
CSB-BP461521EYZ
CSB-MP461521EYZ
CSB-EP461521EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis ATP-dependent protease ATPase subunit HslU (hslU) CSB-YP461522EYZ
CSB-EP461522EYZ
CSB-BP461522EYZ
CSB-MP461522EYZ
CSB-EP461522EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 3-isopropylmalate dehydratase large subunit (leuC) CSB-YP461523EYZ
CSB-EP461523EYZ
CSB-BP461523EYZ
CSB-MP461523EYZ
CSB-EP461523EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Acetylglutamate kinase (argB) CSB-YP461524EYZ
CSB-EP461524EYZ
CSB-BP461524EYZ
CSB-MP461524EYZ
CSB-EP461524EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 50S ribosomal protein L3 (rplC) CSB-YP461525EYZ
CSB-EP461525EYZ
CSB-BP461525EYZ
CSB-MP461525EYZ
CSB-EP461525EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 30S ribosomal protein S8 (rpsH) CSB-YP461526EYZ
CSB-EP461526EYZ
CSB-BP461526EYZ
CSB-MP461526EYZ
CSB-EP461526EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Probable UDP-N-acetyl-D-mannosaminuronic acid transferase (wecG) CSB-YP461527EYZ
CSB-EP461527EYZ
CSB-BP461527EYZ
CSB-MP461527EYZ
CSB-EP461527EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis tRNA pseudouridine synthase D (truD) CSB-YP461528EYZ
CSB-EP461528EYZ
CSB-BP461528EYZ
CSB-MP461528EYZ
CSB-EP461528EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Primosomal replication protein n (priB) CSB-YP461529EYZ
CSB-EP461529EYZ
CSB-BP461529EYZ
CSB-MP461529EYZ
CSB-EP461529EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×